XNAS · APLM
-5.02% · -$1.22 · Vol 1.1K
Market closed · last close 4:00 PM ET · price as of 15:05:35 ET
Apollomics Inc. Class A Ordinary Shares

Apollomics Inc. Class A Ordinary Shares

$23.11
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
APLM
Apollomics Inc. Class A Ordinary Shares
Mon Aug 24 · last completed session · Markets closed · resumes Tue 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Mon Aug 24 · last completed session · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is APLM moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading APLM catalysts
About Apollomics Inc. Class A Ordinary Shares
Listed since
2023
Employees
15
Country
US

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$25.00
Day high
$25.00
Day low
$22.80
Previous close
$24.33
52W high
$36.65
-36.95% from high
52W low
$3.93
59% of range
Market cap
$70.5M
Beta
-1.71
Shares out
2.9M
Volume
1.1K
0.03× rel vol
Avg volume
36.7K
VWAP
$23.77
Price history computed in-house
1W
-3.40%
1M
+26.89%
3M
+65.76%
1Y
+265.04%
YTD
+23.60%
SMA 50 $18.96 · above
SMA 200 $17.52 · above
52W position 59%

APLM overview

Veridion Score
65
Registered · 2026-08-24
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around APLM.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading APLM Form 4 filings
Public disclosures

Congress activity in APLM

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for APLM in the cached public ledger.

Federal contracts

APLM contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for APLM in this window.
Lobbying spend

APLM lobbying filings, year to date.

Registered lobbying filings matched to Apollomics Inc. Class A Ordinary Shares.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for APLM in this window.
Loading news for APLM
Analyst ratings
Sovereign unlock shows live analyst consensus for APLM.
Options
Sovereign unlock shows live options positioning for APLM.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.